VP, Orthopaedic, Inc. North America appointed

RNS Number : 7141O

Tissue Regenix Group PLC

11 February 2016

 

Tissue Regenix Group plc

Appointment of Vice President of Tissue Regenix Orthopaedic, Inc. North America

York, 11 February 2016 - Tissue Regenix Group plc (AIM:TRX)  ("Tissue Regenix") or ("The Group") the regenerative medical devices company, is pleased to announce  the appointment of Drew Distin as Vice President ("VP") of the Group's recently established subsidiary, Tissue Regenix Orthopaedic, Inc. North America. Drew will commence the role as of March 1^st 2016.

Drew is well respected within the Orthopaedic sector in the United States having held a number of senior sales and business development roles at Parkus Medical, LLC. Osiris Therapeutics, Inc. Nuortho Surgical, Inc. RTI Biologics, Inc. and CryoLife, Inc.

With specialist knowledge in maximising sales through targeted marketing, he joins Tissue Regenix as it embarks on the next stage of commercialisation with its dCELL® Orthopaedic applications.  His focus will be to drive their entry into the US marketplace in the coming years, with the first step expected to begin in 2017.

Currently, the Group have ongoing clinical trials for the OrthoPure XM (Porcine meniscus) and OrthoPure XT (Porcine tendon) products within the EU and aim to achieve CE mark submission by the end of the year for XM.

In the US, it is expected that the market entry strategy will focus on human tissue applications, initially starting with the human tendon (OrthoPure HT). Tissue Regenix is currently in partnership with tissue bank Community Tissue Services (CTS) for the manufacturing of its wound care product DermaPure®, and this licencing model is one which the Group expects to replicate with relevant Orthopaedic partners. 

Peter Hamer, Commercial Director, Tissue Regenix Orthopaedic Ltd, said:

"We are delighted to welcome Drew to the Orthopaedic team. He brings with him a wealth of experience that will be advantageous throughout the next stages of our commercialisation and the expansion of our Orthopaedic portfolio. This is a very exciting time for Orthopaedics at Tissue Regenix as we continue enrolment of our OrthoPure XT clinical trial and await submission for the CE mark with OrthoPure XM. We are on course to complete these tasks within the timeline predicted and look forward to further expansion into the US with Drew on board."

For more information:

Tissue Regenix Group plc Caitlin Pearson - Corporate Communications Officer	Tel: [phone]
Jefferies International Ltd Simon Hardy / Harry Nicholas	Tel:  [phone]
Tulchan Communications James Macey-White / Matt Low	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

 In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

NRADBLFFQLFFBBV